RxDoctor Payments Data

Lyudmila Magakyan Martinez, NP

Dermatology · New York, NYNPI 1255757134

Payments from drug & device makers

$4,878in general payments, 2019–2025

Across 329 payments — averaging $14.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$956
  • Pfizer$577
  • Sun Pharmaceutical Industries Inc.$407
  • Johnson & Johnson$367
  • Novartis$363
  • Sanofi-aventis U.S. LLC$334
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$4,20786%
  • Education$67114%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,878 in reported general payments places this provider in the 60th percentile of 1,151 dermatology providers in New York.

See all dermatology providers in New York

Medicare billing

Part B allowed, 2024
$4,568
Medicare patients
20
Services billed
47

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OlumiantBaricitinib97$369,898
Skyrizi PenRisankizumab-Rzaa15$288,910
TremfyaGuselkumab12$161,009
Dupixent PenDupilumab33$128,886
OpzeluraRuxolitinib Phosphate63$122,965
CibinqoAbrocitinib20$107,415
Cosentyx (2 Syringes)Secukinumab11$81,914
Dupixent SyringeDupilumab20$73,874
Pimecrolimus239$65,748
Metronidazole591$42,282
Tacrolimus242$40,380
Fluocinonide354$29,919
Imiquimod75$21,653
EucrisaCrisaborole23$20,699
Triamcinolone Acetonide275$18,293

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlumiant$30$369,89897 claims
Johnson & JohnsonTremfya$367$161,00912 claims
PfizerCibinqo, Eucrisa$577$128,11443 claims
Incyte CorporationOpzelura$154$122,96563 claims
NovartisCosentyx (2 Syringes)$363$81,91411 claims
Arcutis Biotherapeutics, Inc.Zoryve$14$9,85812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,151 dermatology providers in New York.

Other dermatology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →